Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Two large medical studies from Denmark presented in December 2024 provide more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness. These two Danish medical studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many. Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss. We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk. Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss. And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
Mounjaro, Ozempic Vision Loss Lawsuits Filings Increase – 2026 News Reports
The number of vision loss lawsuits filed by patients using Ozempic and Mounjaro has increased, according to major TV news shows and national newspapers. The drug injury lawsuits involve nonarteritic anterior ischemic optic neuropathy (NAION), an eye-related side effect of those two medications and others in the glucagon-like peptide-1 receptor agonists (GLP-1) class of drugs.
To read more of this article, click below:
We begin with a September 21, 2026 NBC News report (video), “Hundreds of lawsuits filed against some GLP-1 Makers over vision loss“.
And from among the many newspaper articles about these vision loss lawsuits, we get the following from a September 18, 2026 article published by the Wall Street Journal, “Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss“:
Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl; she could see straight ahead but not to her right or down.
Two weeks later, a doctor diagnosed Fennell, 53 years old, with nonarteritic anterior ischemic optic neuropathy, or NAION, a condition that leads to sudden, often permanent vision loss.
The doctor asked what medicines she was taking. “He said right away, stop taking Ozempic,” to protect her remaining vision, said Fennell, who started taking the drug to treat her Type 2 diabetes six months prior. “I was shocked.”…
Fennell is one of dozens of people suing Novo, maker of the popular weight-loss and diabetes drugs Wegovy and Ozempic, claiming the medication caused this side effect
As background, to better understand what is behind this increase in vision loss lawsuit filings:
- The active ingredient semaglutide has been linked to NAION; Ozempic as well as Wegovy are semaglutide-containing drugs.
- The active ingredient tirzepatide has been linked to NAION; Mounjaro as well as Zepbound are tirzepatide-containing drugs.
- NAION is sometimes called an “eye stroke,” and it occurs when the optic nerve does not receive enough blood flow.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
- As of today (September 23, 2026), the drug labels for Ozempic, Wegovy, Mounjaro, and Zepbound do not include warnings about the NAION eye-related side effect of these medications and other GLP-1 drugs.
- Based on this failure to warn about NAION and the vision loss resulting from this serious side effect, NAION drug injury lawsuits have been filed against the responsible pharmaceutical companies seeking legal compensation for patients diagnosed with NAION and suffering vision loss.
Long before these 2026 newspaper articles and TV news reports about the vision loss lawsuit filings increase — since back in the summer of 2024 — we have been investigating drug injury lawsuits for patients who used Ozempic, Wegovy, Mounjaro, or Zepbound and have been diagnosed with NAION, or an “eye stroke”.
These NAION vision loss lawsuits for patients using Ozempic or Wegovy would be filed against Novo Nordisk, which last week announced it had shortened its name to “Novo”. For more, see our Drug Injury Law information page for this set of vision loss lawsuits: Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss.
Drug injury NAION vision loss lawsuits involving Mounjaro or Zepbound for patients with vision loss would be filed against Eli Lilly. For more about this set of vision loss lawsuits: Zepbound and Mounjaro Eye Side Effect NAION Information Page
For these vision loss lawsuits, we offer an online case evaluation service that is free and confidential, and without obligation:
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Experienced drug injury attorney Tom Lamb reviews each one of these online Case Evaluation Form submissions. Or call him at 910-256-2971 to discuss a possible NAION vision loss lawsuit.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- NAION Cases Filed in Courts for Vision Loss Legal Compensation
- Ozempic Eye Side Effect NAION Warnings Update July 2026
- Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss
- NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits
- A Rybelsus Blood Clots DVT Case
- Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages